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The inoculation of a single dose of Complete Freund's Adjuvant (CFA) in Dark Agouti
rats induces a polyarttritis that resembles rheumatoid arthritis (RA) in humans. The
specific role of T cells in the pathogenesis of RA is controversial but a considerable body
of evidence suggests that the joint destruction is mediated by T cells within the synovium,
which may activate other cells such as macrophages and fibroblasts that are more directly
implicated in articula¡ damage. To gain a further understanding of the mechanisrns
involved in the development of T cell-mediated polyarthritis, the activation and phenotype
of CD4* T cells during the prodrome of adjuvant-induced arthritis (AA) has been
investigated in rats.
Research in the Arthritis Research Laboratory has demonstrated previously that activated
CD4* T cells in the thoracic duct (TD) lymph of rats during the late prodromal phase of
AA (9 days after inoculation) have the capacity to entff both normal and inflamed joints
after the adoptive transfer to syngeneic recipients. Furthermore, these activated CD4* T
cells can transfer disease to naive recipient rats. The arthritogenic population is contained
within a subset of cD4* T cells that expresses cD25, MHC class II, cDI34and cD7l.
The delay in onset of AA after inoculation with adjuvant (9-10 days) or adoptive transfer
of arthritogenic TD lymphocytes (4-6 days) suggests that progressive differentiation or
selection of effector cells is required before disease can be expressed. This study has
charted the emergence of activated and arth¡itogenic CD4* T cells in the inguinal and
popliteal lymph nodes draining the site of inoculation, in the TD lymph and in the joints
of the hind paws. In the lymph nodes and TD lymph, the proportion of cD4* T cells
expressing activation markers such as cD25, MHC class II, cD13 4 and. cDTr and
adhesion molecules such as ICAM-I increased within 3 days following inoculation of
CFA and these levels remained elevated throughout the early stages of AA. Arthritogenic
lymphocytes vr'ere present in the TD lymph by the fourth day after inoculation of CFA.
Interestingly, the disease transferred to recipients by lymphocytes from a.donor on the
fourth day post-inoculation followed similar kinetics to that transferred by TD
lymphocytes harvested from donors at later time points. Very few CD4* T cells were
detected in the hind paws during the prodrome of AA, whereas a dramatic influx was
observed by day 9 and even more so af day 12 post-inoculation, rvhen joint inflammation
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was usually moderate to severe. These CD4* T cells in the inflame<J hintl paws had
effector phenotYPe.
A method was developed for detecting the cytokine production by individual T
lymphocytes under conditions that reflected the cytokine production by these cells in vivo.
This technique revealed that CD4* T cells from arthritic rats produced more interferon
(iFN)-y than interleukin (IL)-4, suggesting that this disease was mediated by T helper type
-l cells. CD4* T cells from inflamed joints were prolific producers of IFN-y, suggesting
that this pro-inflammatory cytokine may have played a crucial role in disease pathology.
However, when a monoclonal antibody was used to block IFN-y produced by either
transferred arthritogenic lymphocytes or host cells in the active disease, the arthritis was
markedly exacerbated, indicating that this cytokine also has down-regulatory effects at an
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